GSTM1 Tissue Genotype as a Recurrence Predictor in Non-muscle Invasive Bladder Cancer.
10.3346/jkms.2011.26.2.231
- Author:
Yun Sok HA
1
;
Chunri YAN
;
Pildu JEONG
;
Won Tae KIM
;
Seok Joong YUN
;
Isaac YI KIM
;
Sung Kwon MOON
;
Wun Jae KIM
Author Information
1. Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea. wjkim@chungbuk.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Urinary Bladder Neoplasms;
Tumor Markers, Biological;
GSTM1;
Glutathione S-Transferase T1
- MeSH:
Aged;
*Genotype;
Glutathione Transferase/*genetics;
Humans;
Isoenzymes/*genetics;
Kaplan-Meier Estimate;
Middle Aged;
Prognosis;
Proportional Hazards Models;
Recurrence;
Tumor Markers, Biological/metabolism;
Urinary Bladder Neoplasms/diagnosis/*genetics/pathology/*prevention & control
- From:Journal of Korean Medical Science
2011;26(2):231-236
- CountryRepublic of Korea
- Language:English
-
Abstract:
Tissue genotyping is more useful approach than using blood genomic DNA, which can reflect the effects of the somatic mutations in cancer. Although polymorphisms in glutathione S-transferase (GST) have been associated with the risk of bladder cancer (BC) development, few reports provide information about the prognosis of BC. We investigated glutathione S-transferase mu (GSTM1) and glutathione S-transferase theta (GSTT1) genotypes using genomic DNA from primary 165 BC tissue samples to assess the association with disease prognosis. DNA samples from tumor were analyzed by multiplex polymerase chain reaction (PCR). The results were compared with clinicopathological parameters. The prognostic significance of the GSTs was evaluated by Kaplan-Meier and multivariate Cox regression model. Kaplan-Meier estimates revealed significant differences in time to tumor recurrence according to the GSTM1 tissue genotype (P = 0.038) in non-muscle invasive bladder cancer (NMIBC). Multivariate Cox regression analysis also revealed that the tissue GSTM1 genotype (hazards ratio [HR]: 0.377, P = 0.031) was an independent predictor of bladder tumor recurrence in NMIBC. This identification of GSTM1 tissue genotype as a prognosticator for determining recurrence in NMIBC should prove highly useful in a clinical setting.
